237 results on '"Hoque, Mohammad Obaidul"'
Search Results
2. Supp Figure 4 from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
3. Supp Figure 1 from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
4. Supp Figure 3 from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
5. Supp Figure legends from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
6. Supp Figure 3 continued from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
7. Supp Figure 2A from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
8. Supp Table 1, Supp Table 2 from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
9. Data from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
10. Supplementary Table S4 from A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA
11. Supplementary Table 2 from Association between Lifestyle Factors and CpG Island Methylation in a Cancer-Free Population
12. Supplementary information from A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA
13. Data from Changes in CpG Islands Promoter Methylation Patterns during Ductal Breast Carcinoma Progression
14. Supplementary Data from An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-Free Serum DNA
15. Supplementary Table 2 from Pharmacologic Unmasking of Epigenetically Silenced Genes in Breast Cancer
16. Supplementary Tables 1-4 from Changes in CpG Islands Promoter Methylation Patterns during Ductal Breast Carcinoma Progression
17. Supplementary Table 1 from Association between Lifestyle Factors and CpG Island Methylation in a Cancer-Free Population
18. Supplementary Table 1 from Pharmacologic Unmasking of Epigenetically Silenced Genes in Breast Cancer
19. Data from Pharmacologic Unmasking of Epigenetically Silenced Genes in Breast Cancer
20. Supplementary figures 1-4 from Changes in CpG Islands Promoter Methylation Patterns during Ductal Breast Carcinoma Progression
21. Supplementary Table 3 from Pharmacologic Unmasking of Epigenetically Silenced Genes in Breast Cancer
22. Data from An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-Free Serum DNA
23. Data from Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome
24. Supplementary Table 6 from Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome
25. Supplementary Figure 1 from N-Methyl-d-Aspartate Receptor Type 2B Is Epigenetically Inactivated and Exhibits Tumor-Suppressive Activity in Human Esophageal Cancer
26. Data from Mitochondrial Cytochrome B Gene Mutation Promotes Tumor Growth in Bladder Cancer
27. Supplementary Table 8 from Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome
28. Supplementary Figure 2 from N-Methyl-d-Aspartate Receptor Type 2B Is Epigenetically Inactivated and Exhibits Tumor-Suppressive Activity in Human Esophageal Cancer
29. Supplementary Figure Legends 1-4 from Mitochondrial Cytochrome B Gene Mutation Promotes Tumor Growth in Bladder Cancer
30. Supplementary Table 3 from Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome
31. Supplementary Table 5 from Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome
32. Data from N-Methyl-d-Aspartate Receptor Type 2B Is Epigenetically Inactivated and Exhibits Tumor-Suppressive Activity in Human Esophageal Cancer
33. Supplementary Table 1 from Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer
34. Supplementary Table 7 from Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome
35. Supplementary Table 4 from Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome
36. Supplementary Figure 3 from N-Methyl-d-Aspartate Receptor Type 2B Is Epigenetically Inactivated and Exhibits Tumor-Suppressive Activity in Human Esophageal Cancer
37. Supplementary Figures 1-4 from Mitochondrial Cytochrome B Gene Mutation Promotes Tumor Growth in Bladder Cancer
38. Supplementary Table 1 from Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome
39. Supplementary Table 2 from Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome
40. HPV infection-specific hypermethylated genes in oropharyngeal squamous cell carcinomas
41. SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling
42. Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Cancer
43. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer
44. Involvement of aquaporins in colorectal carcinogenesis
45. CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer
46. Genetic and Epigenetic Analysis of erbB Signaling Pathway Genes in Lung Cancer
47. Epigenomics and ovarian carcinoma
48. Forced cytochrome B gene mutation expression induces mitochondrial proliferation and prevents apoptosis in human uroepithelial SV-HUC-1 cells
49. Quantitation of Promoter Methylation of Multiple Genes in Urine DNA and Bladder Cancer Detection
50. Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in Urine Sediment Distinguish Prostate Cancer Patients From Control Subjects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.